Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

Maternal obesity had a strong influence on offspring obesity/severe obesity, and maternal smoking had a significant effect on all 3 outcomes.

There are substantial rural-urban disparities in cardiometabolic risk factors and cardiovascular diseases among US adults.

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

From 2008-2011 to 2020-2023, there was an increase in the prevalence of obesity among youth and adults with T1D, and GLP-1 RA prescriptions also increased.

Federal cuts to funding could “decimate” medical research in the US, delaying cures and costing countless lives.

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with diabetes.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia or cognitive impairment.

Patients with infection-related hospitalization may have increased risk for incident heart failure, including HFrEF and HFpEF.

There may be lower risk for HF among patients with low-to-moderate total alcohol consumption, except in women who drink beer, who may have higher risk.

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.